AU Patent

AU2019299947B2 — Selective estrogen receptor degraders

Assigned to Eli Lilly and Co · Expires 2022-03-17 · 4y expired

What this patent protects

Novel selective estrogen receptor degraders (SERDs) according to the formula:, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R

USPTO Abstract

Novel selective estrogen receptor degraders (SERDs) according to the formula:, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R

Drugs covered by this patent

imlunestrant-tosylate (IMLUNESTRANT TOSYLATE)

Patent Metadata

Patent number: AU2019299947B2
Jurisdiction: AU
Classification: —
Expires: 2022-03-17
Drug substance claim: No
Drug product claim: No
Assignee: Eli Lilly and Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.